One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Regulation of Over-the-Counter Hearing Aids — Deafening Silence from the FDA
Kevin H. Franck, Ph.D., M.B.A., and Vinay K. Rathi, M.D., M.B.A.
doi : 10.1056/NEJMp2027050
N Engl J Med 2020; 383:1997-2000
Transgender Women on College Athletic Teams — The Case of Lindsay Hecox
Janet Dolgin, Ph.D., J.D.
doi : 10.1056/NEJMp2028697
N Engl J Med 2020; 383:2000-2002
An Unexpected Education — Unclaimed Bodies in the Anatomy Lab
Mary Peeler, M.D., M.P.H.
doi : 10.1056/NEJMp2015975
N Engl J Med 2020; 383:2002-2004
Screen Time
Elizabeth Rourke, M.D., and illustrated by Natalie Koscal, M.A.
doi : 10.1056/NEJMp2025321
N Engl J Med 2020; 383:2005
Two Steps Back — Rescinding Transgender Health Protections in Risky Times
Sula Malina, B.A., Sarah Warbelow, J.D., and Asa E. Radix, M.D., Ph.D.
doi : 10.1056/NEJMp2024745
N Engl J Med 2020; 383:e116
Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes
Teresa Quattrin, M.D., Michael J. Haller, M.D., Andrea K. Steck, M.D., Eric I. Felner, M.D., Yinglei Li, Ph.D., Yichuan Xia, Ph.D., Jocelyn H. Leu, Pharm.D., Ph.D., Ramineh Zoka, Pharm.D., Joseph A. Hedrick, Ph.D., Mark R. Rigby, M.D., Ph.D., and Frank Vercruysse, M.D. for the T1GER Study Investigators*
doi : 10.1056/NEJMoa2006136
N Engl J Med 2020; 383:2007-2017
Type 1 diabetes is an autoimmune disease characterized by progressive loss of pancreatic beta cells. Golimumab is a human monoclonal antibody specific for tumor necrosis factor ? that has already been approved for the treatment of several autoimmune conditions in adults and children. Whether golimumab could preserve beta-cell function in youth with newly diagnosed overt (stage 3) type 1 diabetes is unknown.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw, M.D., Ph.D., Todd M. Bauer, M.D., Filippo de Marinis, M.D., Ph.D., Enriqueta Felip, M.D., Ph.D., Yasushi Goto, M.D., Ph.D., Geoffrey Liu, M.D., Julien Mazieres, M.D., Ph.D., Dong-Wan Kim, M.D., Ph.D., Tony Mok, M.D., Anna Polli, B.Sc., Holger Thurm, M.D., Anna M. Calella, Ph.D.,
doi : 10.1056/NEJMoa2027187
N Engl J Med 2020; 383:2018-2029
Lorlatinib, a third-generation inhibitor of anaplastic lymphoma kinase (ALK), has antitumor activity in previously treated patients with ALK-positive non–small-cell lung cancer (NSCLC). The efficacy of lorlatinib, as compared with that of crizotinib, as first-line treatment for advanced ALK-positive NSCLC is unclear.
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group
doi : 10.1056/NEJMoa2022926
N Engl J Med 2020; 383:2030-2040
Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials.
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
Alexandre B. Cavalcanti, M.D., Ph.D., Fernando G. Zampieri, M.D., Ph.D., Regis G. Rosa, M.D., Ph.D., Luciano C.P. Azevedo, M.D., Ph.D., Viviane C. Veiga, M.D., Ph.D., Alvaro Avezum, M.D., Ph.D., Lucas P. Damiani, M.Sc., Aline Marcadenti, Ph.D., Let?cia Kawano-Dourado, M.D., Ph.D., Thiago Lisboa, M.D., Ph.D., Debora L. M. Junqueira, M.D., Pedro G.M. de Barros e Silva, M.D., Ph.D.,
doi : 10.1056/NEJMoa2019014
N Engl J Med 2020; 383:2041-2052
Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.
Endometrial Cancer
Karen H. Lu, M.D., and Russell R. Broaddus, M.D., Ph.D.
doi : 10.1056/NEJMra1514010
N Engl J Med 2020; 383:2053-2064
Wandering Spleen
Alexander Wester, M.D., and Ivan Co, M.D.
doi : 10.1056/NEJMicm2003627
N Engl J Med 2020; 383:2065
Transition Zone in Hirschsprung’s Disease
Shouptik Basu, M.S.
doi : 10.1056/NEJMicm2007613
N Engl J Med 2020; 383:e118
Case 36-2020: A 72-Year-Old Woman with Dark Urine and Weakness
Rajeev Malhotra, M.D., Mayooran Namasivayam, M.B., B.S., Ph.D., Brian B. Ghoshhajra, M.D., Jonathan J. Passeri, M.D., Peter A. Hoenig, M.D., and James R. Stone, M.D., Ph.D.
doi : 10.1056/NEJMcpc2027077
N Engl J Med 2020; 383:2066-2076
Whither Type 1 Diabetes?
Domenico Accili, M.D.
doi : 10.1056/NEJMe2030472
N Engl J Med 2020; 383:2078-2079
Audio Interview: Covid-19 in Europe and New Information on Vaccines
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Charlotte J. Haug, M.D., Ph.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2033666
N Engl J Med 2020; 383:e134
Killing the Pathogen and Sparing the Placenta
Indira U. Mysorekar, Ph.D.
doi : 10.1056/NEJMcibr2028357
N Engl J Med 2020; 383:2080-2082
Physician–Public Defender Collaboration — A New Medical–Legal Partnership
Rahul Vanjani, M.D., Sarah Martino, M.P.A., Sheridan F. Reiger, M.D., M.P.H., James Lawless, M.A., Chelsea Kelly, J.D., Vincent J. Mariano, M.D., and M. Catherine Trimbur, M.D.
doi : 10.1056/NEJMms2002585
N Engl J Med 2020; 383:2083-2086
Rivaroxaban in Peripheral Artery Disease after Revascularization
doi : 10.1056/NEJMc2030413
N Engl J Med 2020; 383:2089-2091
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
doi : 10.1056/NEJMx200021
N Engl J Med 2020; 383:e119
